PDCD1 and cancer: The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death-1/ligand (PD-1/PD-L1) significantly improved treatment of some cancers allowing a longer remission in those cases that previously were considered untreatable [20].